ALK in T-cell lymphoma

1 EU-approved indication in T-cell lymphoma needs a ALK result: crizotinib (2nd line).

Site

Line of therapy

Approved indications, T-cell lymphoma
DrugBiomarker requirementRegimenSettingConditions
ALK fusion1
Crizotinib
Xalkori
Monotherapy
2L
Systemic ALCL only; Children and adolescents only; Relapsed or refractory; Age ≥ 1 to < 18 years

4 approvals for T-cell lymphoma need no biomarker and apply whatever the result. All approvals for T-cell lymphoma

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Crizotinib (Xalkori)
    The treatment of paediatric patients (age ≥1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)